Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas
Serum levels of melanoma inhibiting activity (MIA) and S100, both markers in malignant melanoma, are increased only in few patients with non-melanocytic tumors. We examined a series of serum samples from patients with colorectal (CRC) (N=56), gastric (GC) (N=43), pancreatic (PC) (N=29), hepatocellular (HCC) (N=30), cholangiocellular and gallbladder carcinoma (CCC) (N=18). MIA and S100 were measured by commercially available assays. Positive serum levels for MIA and S100 were found in 16.1% and 5.4% of the patients with CRC, 11.6% and 9.3% with GC, 34.5% and 13.8% with PC,0% and 30% with HCC and 16.7% with CCC, respectively. All patients with sera positive for either MIA or S100 suffered from advanced tumors and received palliative treatment. Elevated serum levels of MIA and S100 are frequentin patients with gastrointestinal cancer. Further investigation is warranted to define the role of MIA or S100 seropositivity in gastrointestinal cancer with regard to follow-up.
Keywordsmelanoma inhibiting activity S100 tumor marker ELISA gastrointestinal carcinomas
Guo HBet al.
Clinical significance of serum S100 in metastatic malignant melanoma.Eur J Cancer
: 1898–1902.PubMedCrossRefGoogle Scholar
Bosserhoff AKet al.
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.Cancer Res
: 3149–3153.PubMedGoogle Scholar
Miliotes Get al.
Evaluation of new putative tumor markers for melanoma.Ann Surg Oncol
: 558–563.PubMedCrossRefGoogle Scholar
Von Schoultz Eet al.
Prognostic value of serum analyses of S100b protein in malignant melanoma.Melanoma Res
: 133–137.CrossRefGoogle Scholar
Deichmann Met al.
S100β, MIA and LDH discriminate progressive from non-progressive AJCC stage IV melanoma disease.J Clin Oncol
1999; accepted for publication.Google Scholar
Dietz U, Sandell LJ. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis.J Biol Chem
: 3311–3316.PubMedCrossRefGoogle Scholar
Isobe T, Ishioka N, Okuyama T. Structural relation of two S-100 proteins in bovine brain; subunit composition of S-100a protein.Eur J Biochem
: 469–474.PubMedCrossRefGoogle Scholar
Isobe T, Takahashi K, Okuyama T. S-100a protein is present in neurons of central and peripheral nervous system.J Neurochem
: 1494–1496.PubMedCrossRefGoogle Scholar
Nakajima T, Sato Y, Watanabe S, Sakurai M, Hidaka H. Immunoelectron microscopical demonstration of S100 protein in epidermal Langerhans cells.Biomed Res
: 226–231.Google Scholar
Stefansson K, Wollman R, Jerkovic M. S100 protein in tissue tumors derived from Schwann cells and melanocytes.Pathology
: 261–268.Google Scholar
Hidaka Het al.
Purification and characterization of adipose tissue S100b protein.J Biol Chem
: 2705–2709.Google Scholar
Kato K, Kimura S. S100a protein is mainly located in the heart and striated muscles.Biochim Biophys Acta
: 146–150.PubMedGoogle Scholar
Semba R, Kato K, Isobe T, Kashiwamata S. Purification of S100a protein from rat kidney.Brain Res
: 9–13.PubMedCrossRefGoogle Scholar
Mokuno Ket al.
Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases.J Neurol Sci
: 443–451.PubMedCrossRefGoogle Scholar
Persson Let al.
S-100 protein and neuronspecific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.Stroke
: 911–918.PubMedGoogle Scholar
Fagnart O, Sindic C, Laterre C. Particle counting immunoassay of S-100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.Clin Chem
: 1387–1391.PubMedGoogle Scholar
Aurell A, Rosengren LE, Wikkelsö C, Nordberg G, Haglid KG. The S-100 protein in cerebrospinal fluid: a simple ELISA method.J Neurol Sci
: 157–164.PubMedCrossRefGoogle Scholar
Aurell Aet al.
Determination of S-100 and GFA protein concentrations in cerebrospinal fluid after brain infarction.Stroke
: 1254–1258.PubMedGoogle Scholar
Hardemark HGet al.
S-100 protein and neuronspecific enolase in CSF after experimental traumatic or focal ischemic brain damage.J Neurosurg
: 727–731.PubMedGoogle Scholar
Ingebrigtsen T, Romner B, Kongstad P, Langbakk B. Increased serum concentrations of protein S-100 after minor head injury: a biochemical serum marker with prognostic value?J Neurol Neurosurg Psychiatry
: 103–104.PubMedCrossRefGoogle Scholar
Johnsson Pet al.
Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood.J Cardiothorac Vasc Anesth
: 1–7.CrossRefGoogle Scholar
Gaynor Ret al.
S100 protein: a marker for human malignant melanomas?Lancet
: 869–871.PubMedCrossRefGoogle Scholar
Drier JK, Swanson PE, Cherwitz DL, Wick MR. S100 protein immuno-reactivity in poorly differentiated carcinomas. Immunohistochemical comparison with malignant melanoma.Arch Pathol Lab Med
: 447–452.PubMedGoogle Scholar
Hancock C, Allen BC, Herrera GA. HMB-45 detection in adenocarcinomas.Arch Pathol Lab Med
: 886–890.PubMedGoogle Scholar